Cancer Stem Cell News 6.18 May 10, 2017 | |
![]() |
|
|
|
TOP STORYInvestigators showed that SL-401 also decreases the viability of interleukin-3R-expressing cancer stem-like cells in multiple myeloma. [Leukemia] Abstract |
|
|
|
PUBLICATIONS(Ranked by impact factor of the journal)Using a 3D fibrin gel model, researchers showed that IFN-γ induces tumor-repopulating cells to enter dormancy through an indolamine 2,3-dioxygenase 1 (IDO1)-kynurenine-aryl hydrocarbon receptor (AhR)-p27 dependent pathway. [Nat Commun] Full Article The authors found that paired related homeobox 1, a homeodomain transcription factor that was previously reported to control skeletal development, is expressed in cortical neural progenitors and is required for their self-renewal and proper differentiation. [J Mol Cell Biol] Abstract The authors analyzed the potential to therapeutically target aberrant tyrosine kinase (TK) signaling and to eliminate leukemia stem cells via the multi-TK inhibitor Debio 0617B. Debio 0617B has a unique profile targeting key kinases upstream of STAT3/STAT5 signaling such as JAK, SRC, ABL and class III/V receptor TKs. [Mol Cancer Ther] Abstract | Full Article Scientists report that furin is unique among the proprotein convertases subtilisin/kexin in being highly expressed in human glioma-initiating cells. Furin cleaves and promotes activation of pro–TGF-β1 and pro–TGF-β2, and TGF-β2 in turn increases furin levels. [J Immunol] Abstract Scientists found that HOXA4 and HOXA9 are up-regulated in colorectal cancer stem cells (CRC SCs). siRNA knockdown of HOXA4 and HOXA9 reduced: proliferation and sphere-formation and gene expression of known SC markers. These results indicate that proliferation and self-renewal ability of CRC SCs are reduced in HOXA4 and HOXA9 knockdown cells. [J Cell Physiol] Abstract Investigators used SF188 and SJ-GBM2 cell lines to study the function of UCHL1, a deubiquitinase de-regulated in several cancers, in pediatric high-grade gliomas. UCHL1 depletion in SF188 and SJ-GBM2 glioma cells was associated with decreased cell proliferation and invasion, along with a reduced ability to grow in soft agar and to form spheres. [PLoS One] Full Article Analysis using sphere-formation culture revealed that Tie receptor 1 (Tie1)-positive cells are enriched within the population of tumor cells with cancer stemness properties. Indeed, Tie1-positive tumor cells derived from a murine model overexpressed Lgr5, a typical stemness marker for colorectal cancer. [Cancer Med] Full Article TEAD1 Mediates the Oncogenic Activities of Hippo-YAP1 Signaling in Osteosarcoma Investigators demonstrated that TEAD1 was the major transcription factor of Hippo signaling pathway in osteosarcoma (OS). Genetic silencing of TEAD1 suppressed multiple malignant phenotypes of OS cells including cell proliferation, apoptosis resistance, and invasive potential. [Biochem Biophys Res Commun] Abstract Whereas normal CD34+/CD38− bone marrow stem cells displayed only low amounts of CD25 or lack CD25, CD34+/CD38− leukemic stem cells strongly expressed CD25 in over 90% of all patients with untreated chronic myeloid leukemia. [Exp Hematol] Abstract |
|
|
|
REVIEWSIn this review, recent advances achieved in the characterization of cancer stem cells derived from hematological malignancies, with a particular focus on multiple myeloma, are discussed and major natural products that target cancer stem cells are presented. [Planta Med] Full Article Visit our reviews page to see a complete list of reviews in the cancer stem cell research field. |
|
|
|
INDUSTRY NEWSBristol-Myers Squibb Company and Calithera Biosciences, Inc. announced the companies have expanded their existing collaboration to evaluate Bristol-Myers Squibb’s Opdivo in combination with Calithera’s CB-839 in patients with non-small cell lung cancer and melanoma. [Bristol-Myers Squibb Company] Press Release The Pershing Square Sohn Cancer Research Alliance announced the six winners of the fourth annual Pershing Square Sohn Prize for Young Investigators in Cancer Research, awarded annually to promising early career, NYC-area scientists. Recipients receive $200,000 in funding per year for up to three years, for a total of $600,000, to support explorative, high-risk/high-reward cancer research. [Pershing Square Sohn Cancer Research Alliance] Press Release | |
|
|
POLICY NEWSThe Secret War against Counterfeit Science China is famous for knock-off DVDs, Louis Vuitton bags and Rolex watches. But counterfeit reagents aren’t on sale in busy public markets. They are sold through sophisticated websites, mixed in with legitimate supplies, and sourced and sold using a network of unwitting partners. [Nature News] Editorial Science Publishers Try New Tack to Combat Unauthorized Paper Sharing The unauthorized sharing of copyrighted research papers is on the rise, say analysts who track the publishing industry. Faced with this problem, science publishers seem to be changing tack in their approach to researchers who breach copyright. [Nature News] Editorial Biotech Execs, Academic Leaders Make Case for NIH Funding at White House Meeting Could the Trump administration be changing its mind about slashing funding for the National Institutes of Health (NIH)? Scientific leaders were optimistic after meeting at the White House with several biotech executives to discuss the “ecosystem” in which federally funded basic research leads to discoveries that companies turn into treatments. [ScienceInsider] Editorial
|
|
EVENTSNEW Summit for Cancer Immunotherapy 2017 Visit our events page to see a complete list of events in the community.
|
|
JOB OPPORTUNITIESNEW Research Scientist – Leukemia (The University of Texas MD Anderson Cancer Center) Postdoctoral Associate – Cancer Biology/Immunology/Leukemia Research (University of Miami) Postdoctoral Associate – Cancer Research/Oncology (University of Miami) Postdoctoral Fellows – Cancer Stem Cell Biology (Genome Institute of Singapore) Research Officers – Cancer Stem Cell Biology (Genome Institute of Singapore) Postdoctoral Fellows – Cancer Biology (University of Texas Medical School at Houston) Postdoctoral Fellow – Breast Cancer Stem Cell (University of Kentucky) Postdoctoral Position – Stem Cell Research (Helmholtz Association) Postdoctoral Fellow – Cell Cycle Control and Tumorigenesis (Fred Hutchinson Cancer Research Center) Postdoctoral Fellow – Ubiquitin System and Cancer (Fred Hutchinson Cancer Research Center)
Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
|
|
Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. |
|
|